ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0748

Does The Number Of Arteries Affected At The Disease Onset Predict Relapses Of Giant Cell Arteritis?

Iztok HOLC1, Metka Koren Krajnc2, Marko Gačnik3 and Anja Lah4, 1University Medical Center Maribor, 2000 Maribor, Slovenia, 2University Medical center, Maribor, Slovenia, 3University Medical Center Maribor, Braslovče, Slovenia, 4University Medical Center Maribor, Laporje, Slovenia

Meeting: ACR Convergence 2025

Keywords: giant cell arteritis, Outcome measures, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Giant cell arteritis (GCA) is a chronic vasculitis where relapses frequently occur. The rates of relapses of GCA have not been defined by now.We aimed to evaluate the factors associated with relapses in our cohort.

Methods: In 58 GCA patients the diagnosis was confirmed according to history, clinical signs, laboratory tests and ultrasound examination. Ultrasound of cranial, carotid and axillar arteries was performed in all participants. We collected data cross-sectionally at first evaluation and at the second evaluation 5 years later. Predictors of relapses were identified by logistic regression analysis.

Results: 58 GCA patients were included initially (62 % women, mean age 74 years). At the end 53 patients completed the study and their data have been analyzed. 2 (3,4%) patients died, 3 (5,1%) were lost (didn’t show up on controls). All patients received glucocorticoid treatment (60mg ofprednisolone, or pulse treatment if the vision was impaired), during follow up 16 (30,1%) received leflunomide (non-biologic agent as steroid sparing drug), 16 (30,1%) tocilizumab (biologic agent).Relapses occurred in 17 (33,3%) of patients. A Mann-Whitney U value of 0.46 and t test (Welch) indicates that the relationship between the number of affected arteries and the occurrence of relapses in GCA patients is weak or negligible. There were no association with relapse occurrences and the time to diagnosis (t-test value of 0.99, Mann-Whitney 0,62). Mann-Whitney U test 0,07 result provides stronger evidence for a relationship between CRP levels and relapse, while the t-test 0,12 suggests that the mean CRP difference at the time of diagnosis is not substantial enough to be considered clinically significant.

Conclusion: GCA relapses occurred in 33,3 % of patients. Relapses were not associated with number of affected arteries, with the value of CRP at the time of diagnosis or with the time to diagnosis


Disclosures: I. HOLC: Roche, 6; M. Koren Krajnc: None; M. Gačnik: None; A. Lah: None.

To cite this abstract in AMA style:

HOLC I, Koren Krajnc M, Gačnik M, Lah A. Does The Number Of Arteries Affected At The Disease Onset Predict Relapses Of Giant Cell Arteritis? [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/does-the-number-of-arteries-affected-at-the-disease-onset-predict-relapses-of-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-the-number-of-arteries-affected-at-the-disease-onset-predict-relapses-of-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology